Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Erritzoe

Showing results (11-20 of 142) with videos related to

Pageof 15
Sort By:
JAMA Network Open|July 15, 2024
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience EfficacyLeor Roseman, David Erritzoe, David Nutt, et al.
Scientific Reports|September 25, 2023
Case analysis of long-term negative psychological responses to psychedelicsRebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Nature Reviews. Neuroscience|April 16, 2015
The dopamine theory of addiction: 40 years of highs and lowsDavid J Nutt, Anne Lingford-Hughes, David Erritzoe, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 20, 2025
The role of GABA, glutamate, and Glx levels in treatment of major depressive disorder: A systematic review and meta-analysisKate Godfrey, Hannah Douglass, David Erritzoe, et al.
Acta Psychiatrica Scandinavica|October 30, 2020
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studiesKristoffer A A Andersen, Robin Carhart-Harris, David J Nutt, et al.
Journal of Psychopharmacology (Oxford, England)|October 28, 2025
A long, strange trip: Ketamine treatment in psychiatryDavid J Nutt, Celia Morgan, David Erritzoe, et al.
Journal of Psychopharmacology (Oxford, England)|May 1, 2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depressionBrandon Weiss, David Erritzoe, Bruna Giribaldi, et al.
Psychological Medicine|January 22, 2024
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depressionBalázs Szigeti, Brandon Weiss, Fernando E Rosas, et al.
Journal of Affective Disorders|February 29, 2024
Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivityDébora Copa, David Erritzoe, Bruna Giribaldi, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 19, 2026
Recent advances in PET measures of brain 5-HT releaseClaudio Agnorelli, Hanne Demant Garling, Louise M Paterson, et al.
Pageof 15

Showing results (11-20 of 142) with videos related to

Sort By:
Pageof 15
JAMA Network Open|July 15, 2024
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience EfficacyLeor Roseman, David Erritzoe, David Nutt, et al.
Scientific Reports|September 25, 2023
Case analysis of long-term negative psychological responses to psychedelicsRebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Nature Reviews. Neuroscience|April 16, 2015
The dopamine theory of addiction: 40 years of highs and lowsDavid J Nutt, Anne Lingford-Hughes, David Erritzoe, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 20, 2025
The role of GABA, glutamate, and Glx levels in treatment of major depressive disorder: A systematic review and meta-analysisKate Godfrey, Hannah Douglass, David Erritzoe, et al.
Acta Psychiatrica Scandinavica|October 30, 2020
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studiesKristoffer A A Andersen, Robin Carhart-Harris, David J Nutt, et al.
Journal of Psychopharmacology (Oxford, England)|October 28, 2025
A long, strange trip: Ketamine treatment in psychiatryDavid J Nutt, Celia Morgan, David Erritzoe, et al.
Journal of Psychopharmacology (Oxford, England)|May 1, 2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depressionBrandon Weiss, David Erritzoe, Bruna Giribaldi, et al.
Psychological Medicine|January 22, 2024
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depressionBalázs Szigeti, Brandon Weiss, Fernando E Rosas, et al.
Journal of Affective Disorders|February 29, 2024
Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivityDébora Copa, David Erritzoe, Bruna Giribaldi, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 19, 2026
Recent advances in PET measures of brain 5-HT releaseClaudio Agnorelli, Hanne Demant Garling, Louise M Paterson, et al.
Pageof 15